Fedratinib (Inrebic, Bristol Myers Squibb) is indicated for 'the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naive or have been treated with ruxolitinib'.
The dosage schedule is available in the summary of product characteristics for fedratinib.
The list price of fedratinib is £6,119.68 for a 120‑capsule pack of 100‑mg capsules (excluding VAT; BNF online, accessed August 2024).
The company has a commercial arrangement. This makes fedratinib available to the NHS with a discount. The size of the discount is commercial in confidence.